comparemela.com

Latest Breaking News On - Biolinerx company profile - Page 1 : comparemela.com

Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Decreases By 46.6%

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 219,100 shares, a decrease of 46.6% from the April 30th total of 410,600 shares. Based on an average daily volume of 410,600 shares, the short-interest ratio is […]

B-riley-wealth-advisors-inc
Rathbones-group
Biolinerx-company-profile
Northrock-partners
Biolinerx-ltd
Nasdaq
First-advisors-inc
Allen-mooney-barnes-investment-advisors
Get-free-report
Rock-partners
Wealth-advisors

BioLineRx (NASDAQ:BLRX) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX – Free Report) to a sell rating in a report published on Tuesday morning. Separately, HC Wainwright reissued a buy rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, April 17th. View Our Latest Analysis on BioLineRx BioLineRx Stock Performance NASDAQ:BLRX […]

Northrock-partners
First-advisors-inc
Biolinerx-ltd
Rathbones-group
Nasdaq
Asset-management-corp
Allen-mooney-barnes-investment-advisors
Biolinerx-company-profile
Free-report
Get-free-report
Management-corp

StockNews.com Upgrades BioLineRx (NASDAQ:BLRX) to Sell

BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th. Check Out Our […]

First-advisors-inc
Biolinerx-ltd
Allen-mooney-barnes-investment-advisors
B-riley-wealth-advisors-inc
Biolinerx-company-profile
Asset-management-corp
Rathbones-group
Get-free-report
Management-corp
First-advisors
Barnes-investment-advisors

BioLineRx (NASDAQ:BLRX) Upgraded at StockNews.com

BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Wednesday, April 17th. Check Out Our Latest Report […]

Northrock-partners
First-advisors-inc
B-riley-wealth-advisors-inc
Allen-mooney-barnes-investment-advisors
Biolinerx-ltd
Rathbones-group
Nasdaq
Biolinerx-company-profile
Get-free-report
Linerx-stock-down
Riley-wealth-advisors

BioLineRx (NASDAQ:BLRX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock. Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a report on Monday, December 4th. View Our Latest Research […]

Renaissance-technologies
Biolinerx-ltd
Envestnet-asset-management-inc
Asset-management-corp
Atria-wealth-solutions-inc
Biolinerx-company-profile
Free-report
Wealth-solutions
Asset-management
Management-corp
Get-free-report

vimarsana © 2020. All Rights Reserved.